| Trial ID: | L0299 |
| Source ID: | NCT04808154
|
| Associated Drug: |
SNP-630
|
| Title: |
A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of SNP-630 in Health Subjects.
|
| Acronym: |
--
|
| Status: |
Completed
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
NASH - Nonalcoholic Steatohepatitis
|
| Interventions: |
Drug: SNP-630
|
| Outcome Measures: |
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs):|Pharmacokinetic profile of SNP-630
|
| Sponsor/Collaborators: |
Sinew Pharma Inc.
|
| Gender: |
All
|
| Age: |
20 Years to 45 Years ?? (Adult)
|
| Phases: |
Phase 1
|
| Enrollment: |
28
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
|
| Start Date: |
July 22, 2021
|
| Completion Date: |
August 31, 2021
|
| Results First Posted: |
--
|
| Last Update Posted: |
October 11, 2021
|
| Locations: |
Tri-Service General Hospital, Taipei, Taiwan
|
| URL: |
https://ClinicalTrials.gov/show/NCT04808154
|
